Sun Chuanhe, Wang Dandan, Jiang Wenfei, Liao Weilong, Gao Penglin, Pan Weidong, Liu Te
Department of Neurology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Evid Based Complement Alternat Med. 2017;2017:3045260. doi: 10.1155/2017/3045260. Epub 2017 Apr 18.
. To evaluate the efficacy of Lian-Se formula (LSF), one Chinese herb formulation for treating sialorrhea and frequent overnight urination in patients with Parkinson's disease (PD). . 96 PD patients suffering from sialorrhea and/or frequent nighttime urination were divided into two groups: an LSF group ( = 48) treated with LSF for 6 weeks and a placebo group ( = 48) treated with a placebo formula whose appearance and taste were the same as LSF for 6 weeks. All patients were treated by standard antiparkinsonism medicine according to the PD guideline of China. The changes of the quantity of saliva (QS) (mL), frequency of nighttime urination (FNU) and early sleep activity (ESA), and nocturnal activity (NA) by analyzing actigraphic records as the primary results and the total score of unified Parkinson's disease rating scale (UPDRS) and the Epworth Sleepiness Scale (ESS) as the secondary results were used to evaluate the clinical efficacy in both groups. . There were no significant differences in the baseline values of QS, FNU, NA, ESA, UPDRS total score, and ESS between the two groups. At the end of week 6, the QS, FNU, NA, and ESA in the LSF group showed superior results to those of the placebo group with no differences in the total UPDRS score between the two groups during the investigation. The ESS was significantly improved at the end of week 6 compared with the baseline and the placebo group. Laboratory test results indicated there were no side effects in either group. . The findings of LSF treatment have clear clinical effects in patients with sialorrhea and frequent overnight urination. LSF thus appears to be a potential choice as an additional drug that can improve the sialorrhea and frequent overnight urination symptoms of PD patients.
为评估连瑟方(LSF)治疗帕金森病(PD)患者流涎及夜尿频繁的疗效。96例患有流涎和/或夜尿频繁的PD患者被分为两组:LSF组(n = 48)接受LSF治疗6周,安慰剂组(n = 48)接受外观和味道与LSF相同的安慰剂配方治疗6周。所有患者均按照中国PD指南接受标准抗帕金森病药物治疗。以分析活动记录仪记录得出的唾液量(QS)(mL)、夜尿频率(FNU)、早睡活动(ESA)和夜间活动(NA)的变化作为主要结果,以统一帕金森病评定量表(UPDRS)总分和爱泼华嗜睡量表(ESS)作为次要结果来评估两组的临床疗效。两组之间QS、FNU、NA、ESA、UPDRS总分和ESS的基线值无显著差异。在第6周结束时,LSF组的QS、FNU、NA和ESA显示出优于安慰剂组的结果,在研究期间两组的UPDRS总分无差异。与基线和安慰剂组相比,第6周结束时ESS显著改善。实验室检查结果表明两组均无副作用。LSF治疗对患有流涎和夜尿频繁的患者有明显临床效果。因此,LSF似乎是一种潜在的选择,作为一种可以改善PD患者流涎和夜尿频繁症状的附加药物。